Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

Table 2 Treatment-Related Outcomes at 12 Months by Treatment Status at Enrollment, REACH-OUT (2010–2013)

Variable	PP-All N = 482	PP-C N = 308	PP-N N = 174	OAT (N = 281)	P Value, PP-All vs OAT	P Value, PP-N vs OAT
Discontinuation	62 (20%)	34 (17%)	28 (27%)	92 (51%)	<0.001	<0.001
MPR (mean ± SD)	0.84 ± 0.20	0.85 ± 0.17	0.82 ± 0.23	0.52 ± 0.31	<0.001	<0.001
Nonadherence (MPR <80%)	118 (26%)	74 (25%)	44 (28%)	194 (75%)	<0.001	<0.001
Adherence (MPR ≥80%)	332 (74%)	217 (75%)	115 (72%)	66 (25%)
1-year PDC (Mean ± SD)	0.57 ± 0.39	0.60 ± 0.39	0.53 ± 0.39	0.31 ± 0.29	<0.001	<0.001
Nonadherence (PDC <80%)	270 (56%)	164 (53%)	106 (61%)	255 (91%)	<0.001	<0.001
Adherence (PDC ≥80%)	212 (44%)	144 (47%)	68 (39%)	26 (9%)

Notes: (1) Percentages reported are among the nonmissing. Number missing discontinuation: PP-C, 33%; PP-N, 41%; OAT, 36%. Number missing MPR: PP-C, 6%; PP-N, 9%; OAT, 7%. Number missing PDC: PP-C, 0%; PP-N, 0%; OAT, 0%
Abbreviations: MPR medication possession ratio, OAT oral antipsychotic therapy, PDC proportion of days covered, PP paliperidone palmitate, PP-C continuous user of paliperidone palmitate, PP-N new user of paliperidone palmitate, SD standard deviation

ISSN: 1471-244X